IL250388B - Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells - Google Patents

Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

Info

Publication number
IL250388B
IL250388B IL250388A IL25038817A IL250388B IL 250388 B IL250388 B IL 250388B IL 250388 A IL250388 A IL 250388A IL 25038817 A IL25038817 A IL 25038817A IL 250388 B IL250388 B IL 250388B
Authority
IL
Israel
Prior art keywords
cells
attract
express
genetically modified
mesenchymal stem
Prior art date
Application number
IL250388A
Other languages
English (en)
Hebrew (he)
Other versions
IL250388A0 (en
Original Assignee
Apceth Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apceth Gmbh & Co Kg filed Critical Apceth Gmbh & Co Kg
Publication of IL250388A0 publication Critical patent/IL250388A0/en
Publication of IL250388B publication Critical patent/IL250388B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL250388A 2014-08-18 2017-02-01 Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells IL250388B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14181283 2014-08-18
PCT/EP2015/068942 WO2016026854A2 (en) 2014-08-18 2015-08-18 Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

Publications (2)

Publication Number Publication Date
IL250388A0 IL250388A0 (en) 2017-03-30
IL250388B true IL250388B (en) 2021-02-28

Family

ID=51352460

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250388A IL250388B (en) 2014-08-18 2017-02-01 Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

Country Status (8)

Country Link
US (2) US20170239297A1 (enExample)
EP (2) EP3656387A3 (enExample)
JP (1) JP6712993B2 (enExample)
CN (1) CN106659742B (enExample)
AU (1) AU2015306231B2 (enExample)
CA (1) CA2956987C (enExample)
IL (1) IL250388B (enExample)
WO (1) WO2016026854A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
PT3107573T (pt) * 2014-02-19 2019-01-10 Merck Patent Gmbh Imunoterapia com il-12 visada ao cancro
CN108884440A (zh) 2016-04-01 2018-11-23 埃普塞斯有限责任两合公司 用于增强免疫疗法的抗肿瘤活性的间充质干细胞
US11529393B2 (en) 2016-10-10 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use
CN108148862B (zh) * 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
EP3595684A1 (en) * 2017-03-17 2020-01-22 Senti Biosciences, Inc. Immunomodulating cell circuits
EP3606540A1 (en) * 2017-04-07 2020-02-12 Cynata Therapeutics Limited Method for treating a side effect of chimeric antigen receptor (car) t cell therapy
SG10202111394XA (en) 2017-04-13 2021-12-30 Senti Biosciences Inc Combinatorial cancer immunotherapy
CN107184603B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
CN107184602B (zh) * 2017-06-01 2020-06-30 刘未斌 一种治疗肿瘤的药物组合
AU2018285953A1 (en) * 2017-06-16 2020-01-16 Cynata Therapeutics Limited Method for treating a side effect of immunotherapy
WO2019067491A1 (en) * 2017-09-29 2019-04-04 Oncocyclist, Inc. COMPOSITION AND METHOD FOR TREATING CELL PROLIFERATION
WO2019104037A1 (en) 2017-11-22 2019-05-31 The Brigham And Women's Hospital, Inc. Msc-expressed immunomodulators in combination with car-t for cancer therapy
SG10201900072VA (en) 2018-01-05 2019-08-27 Gnt Biotech & Medicals Corp A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
KR20200108316A (ko) * 2018-01-12 2020-09-17 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 세포 리프로그래밍 요법
KR20200058322A (ko) 2018-01-25 2020-05-27 아이-맵 바이오파마 유에스 리미티드 항-pd-l1 항체 및 il-7 융합체
EP3747459A4 (en) * 2018-02-02 2021-12-01 SL Vaxigen, Inc. NEW IMMUNOADJUVANT VACCINE
WO2019179400A1 (en) * 2018-03-21 2019-09-26 China Medical University Engineering stem cells for cancer therapy
CN108864288A (zh) * 2018-04-26 2018-11-23 上海怡豪生物科技有限公司 乳腺癌的双靶点car-t治疗载体及其构建方法和应用
CN110527696A (zh) * 2018-06-13 2019-12-03 中山大学 一种IFNβ和FerritinH基因联合修饰的骨髓间充质干细胞及其制备方法和应用
CN108815188A (zh) * 2018-07-06 2018-11-16 浙江生创精准医疗科技有限公司 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
US20210346430A9 (en) * 2018-08-26 2021-11-11 Oaiscell Biotechnologies Method for treating glioblastoma
CN112771167B (zh) * 2018-09-20 2025-09-26 克莱格医学有限公司 表达有趋化因子的细胞及用途
EP3864142A4 (en) * 2018-10-12 2023-07-19 iCell Gene Therapeutics LLC CHEMERA ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
AU2019359890B2 (en) * 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN109593725A (zh) * 2018-12-25 2019-04-09 河北生命原点生物科技有限公司 一种重组间充质干细胞及其应用
US20220128541A1 (en) * 2019-02-14 2022-04-28 Research Institute At Nationwide Children's Hospital Use of plasma membrane particles, liposomes, and exosomes to assay immune cell potency
CN109762820B (zh) * 2019-02-18 2020-07-28 河北佑仁生物科技有限公司 一种骨髓间充质干细胞特异性启动元件在干细胞中的应用
EP3946440A4 (en) * 2019-04-02 2023-04-19 The General Hospital Corporation Methods to enhance t cell regeneration
CN115851605A (zh) * 2019-04-18 2023-03-28 上海交通大学 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
CN111139222B (zh) * 2019-05-30 2020-12-29 北京双因生物科技有限公司 一种重组间充质干细胞及其制备方法和用途
EP4017512B1 (en) * 2019-08-23 2025-04-02 Orbsen Therapeutics Limited Compositions for monocyte and macrophage polarization and methods of use
WO2021194427A1 (en) * 2020-03-26 2021-09-30 Agency For Science, Technology And Research A method and system for introducing one or more exogenous substances into an immune cell
BR112022016715A2 (pt) * 2020-05-27 2022-11-16 Univ Zuerich Vetores virais que expressam proteínas terapêuticos especificamente em células mieloides e microglia
US20230257713A1 (en) * 2020-07-16 2023-08-17 Shanghai Jiaotong University Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell
US20230399622A1 (en) * 2020-10-16 2023-12-14 Fundació Centre De Regulació Genòmica Therapy for degenerative disease and tissue damage
CN114426953A (zh) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 一种表达il-12的多能干细胞衍生物及应用
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CN114717232A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
WO2023274355A1 (zh) * 2021-07-02 2023-01-05 上海交通大学 改造的间充质干细胞和免疫效应细胞联合治疗肿瘤
WO2023076670A1 (en) * 2021-11-01 2023-05-04 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cells for the prevention and targeted treatment of cancer and other disorders
CN114480413B (zh) * 2022-01-14 2022-11-04 北京贝来生物科技有限公司 一种活化肿瘤免疫应答的基因修饰干细胞制备方法
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途
CN117503952B (zh) * 2022-11-24 2025-09-16 中国药科大学 一种基于血小板的免疫激活系统及其制备方法和应用
WO2024137869A2 (en) * 2022-12-20 2024-06-27 City Of Hope Stem cells for delivery of oncolytic viruses
US20250333700A1 (en) * 2024-02-28 2025-10-30 Gene Solutions Joint Stock Company Modified k562 feeder cell line expressing factors that enhance the activation and proliferation of natural killer cells and a method for its production

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005531507A (ja) 2002-03-02 2005-10-20 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法
JPWO2005007176A1 (ja) * 2003-06-27 2006-08-31 株式会社レノメディクス研究所 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
EP1640898A4 (en) * 2003-06-27 2011-01-12 Nc Medical Res Inc SELF-CELL DELIVERY SUPPORT SYSTEM FOR MEDICAL CARE, SELF-CELL DELIVERY-SUPPORT FINANCIAL SYSTEM FOR MEDICAL SERVICES AND METHOD THEREFOR
US20050002904A1 (en) 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
WO2006031539A2 (en) * 2004-09-10 2006-03-23 Cognate Therapeutics, Inc. Liver stromal cells for prevention and treatment of immune responses in transplantation
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
BRPI0811906A2 (pt) * 2007-05-24 2014-11-18 Apceth Gmbh & Co Kg Composições e métodos relacionados a célula-tronco cd34
EP2019134A1 (en) 2007-07-26 2009-01-28 Vision 7 GmbH Gene therapy of chronic granulomatous disease
KR20120088542A (ko) 2009-04-13 2012-08-08 아프세스 게엠베하 & 씨오. 카게 종양 치료를 위한 조작된 중간엽 줄기세포 및 이를 사용하는 방법
BR112012013780B8 (pt) * 2009-12-08 2021-07-27 Univ Illinois biorreator para modular linfócitos e suprimir células t autorreativas, sistema para inibição de um distúrbio autoimune, e, método ativar células t reguladoras
CN101974485A (zh) * 2010-11-12 2011-02-16 苏州大学 具有最佳迁移能力的间充质干细胞的制备方法及其应用
US9101597B2 (en) 2013-03-14 2015-08-11 The Administration Of The Tulane Educational Fund Immunoprotective primary mesenchymal stem cells and methods
AR097570A1 (es) * 2013-09-06 2016-03-23 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Composiciones y métodos para incrementar la migración de células mesenquimales del estroma hacia tumores
ES2963718T3 (es) * 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells

Also Published As

Publication number Publication date
EP3182984B1 (en) 2019-10-30
US11464806B2 (en) 2022-10-11
AU2015306231A1 (en) 2017-02-23
US20170239297A1 (en) 2017-08-24
CN106659742A (zh) 2017-05-10
CA2956987C (en) 2023-03-21
CA2956987A1 (en) 2016-02-25
WO2016026854A2 (en) 2016-02-25
EP3182984A2 (en) 2017-06-28
EP3656387A2 (en) 2020-05-27
AU2015306231B2 (en) 2019-11-21
EP3656387A3 (en) 2020-07-01
JP6712993B2 (ja) 2020-06-24
CN106659742B (zh) 2021-09-03
WO2016026854A3 (en) 2016-04-14
US20200268802A1 (en) 2020-08-27
JP2017525364A (ja) 2017-09-07
IL250388A0 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
IL250388B (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
IL253248A0 (en) Natural killer cells and their uses
IL259586B (en) Genetically modified stem cells and uses thereof
EP3562492A4 (en) GENETICALLY MODIFIED NATURAL KILLER CELLS
SG11201609118RA (en) Modified natural killer cells and uses thereof
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
IL250952A0 (en) Mir-29 mimics and uses thereof
DK3094351T3 (da) Immunmodulatoriske midler
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
MA40595A (fr) Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire
DK2939628T3 (da) Multielektrode-ballonkateter med periferi- og punktelektroder
MA47580A (fr) Cellules immunitaires bipartites et tripartites de signalisation
PT3841877T (pt) Ratinhos geneticamente modificados que expressam epo humana
EP3092318A4 (en) Methods for defining and predicting immune response to allograft
HUE053760T2 (hu) SUV39h1-deficiens immunsejtek
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
GB201401528D0 (en) Social matching and interaction
IL259202A (en) Modified immune cells and uses thereof
DK3228312T3 (da) Immunregulator
DE112015003841A5 (de) Di- und triphosphat-propharmaka
HUE047455T2 (hu) HPA-1A elleni antitestek
IL231653B (en) Aircraft pylon
DK2993037T3 (da) Fyldt metalsandwichstruktur
GB201421430D0 (en) Antibodies to Adam17 and uses thereof
DK3134118T3 (da) Partikelformede vaccineformuleringer til fremkaldelse af medfødt og adaptiv immunitet

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed